Taxane anticancer agents: a patent perspective

Volume: 26, Issue: 1, Pages: 1 - 20
Published: Jan 1, 2016
Abstract
Introduction:Paclitaxel and docetaxel were two epoch-making anticancer drugs and have been successfully used in chemotherapy for a variety of cancer types. In the year 2010, a new taxane, cabazitaxel, was approved by FDA for use in combination with prednisone for the treatment of metastatic hormone-refractory prostate cancer. Albumin-bound paclitaxel (nab™-paclitaxel; abraxane) nanodroplet formulation was another notable invention (FDA approval...
Paper Fields
Paper Details
Title
Taxane anticancer agents: a patent perspective
Published Date
Jan 1, 2016
Volume
26
Issue
1
Pages
1 - 20
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.